A5087941454- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Glioma Diagnosis and Treatment
- Maternal and Neonatal Healthcare
- SARS-CoV-2 and COVID-19 Research
- Magnetic Properties of Alloys
- Immunodeficiency and Autoimmune Disorders
- Fungal Infections and Studies
- Endometrial and Cervical Cancer Treatments
- Nail Diseases and Treatments
- Antifungal resistance and susceptibility
- Magnetic Properties and Applications
- Viral-associated cancers and disorders
- Pregnancy and preeclampsia studies
- Ovarian cancer diagnosis and treatment
- Magnetic properties of thin films
- Global Maternal and Child Health
AC Camargo Hospital
2022-2024
Universidade Estadual de Campinas (UNICAMP)
1993-2021
Hematological malignancy (HM) patients treated with anti-CD20 monoclonal antibodies are at higher risk for severe COVID-19. A previous single-center study showed worse outcomes in obinutuzumab compared to rituximab. We examined this hypothesis a large international multicenter cohort.
Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with underlying malignancies prior transplants. FDA approved Isavuconazole as primary therapy for Aspergillosis (IA) Mucormycosis. This study aims to compare the real-world clinical outcomes safety isavuconazole voriconazole an amphotericin B-based regimen in transplant. In addition, response anti-fungal outcome were compared disparity (elderly, obese patients, renal insufficiency...
Despite the declining public health emergency status, COVID-19 still poses significant risks, especially for immunocompromised individuals. We aimed to evaluate effectiveness of tixagevimab-cilgavimab (T-C) prophylaxis in preventing severe patients with hematologic malignancies (HM) treated anti-CD20 therapy during early Omicron variant phase pandemic.
Abstract Background Hematological malignancy (HM) patients treated with anti-CD20 monoclonal antibodies are at higher risk for severe COVID-19 and adverse outcomes. A previous single-center study showed worse outcomes in obinutuzumab than those rituximab. Methods This is an international, multi-center population-based across 15 centers (Israel, USA, Spain, Brazil, Turkey). We included HM or rituximab between December 2021 June 2022, when Omicron lineage variants were dominant. Results...
Introduction: Diffuse large B-cell lymphoma (DLBCL) is clinically, morphologically and genetically a heterogeneous group of malignant proliferation lymphoid cells. At diagnosis, 25% DLBCL presents as localized disease. Therapeutic options for include short-course or extended-course chemotherapy regimens such R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with without radiotherapy. Regarding the number cycles, choice differs in different oncology services role...